CARA Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -488.11% compared to Cara Therapeutics's net margin of 11.99%. Cara Therapeutics's return on equity of -258.41% beat Johnson & Johnson's return on equity of 20.88%.

Cara Therapeutics has a consensus price target of $1.01, signalling upside risk potential of 117.86%. On the other hand Johnson & Johnson has an analysts' consensus of $172.53 which suggests that it could grow by 19.49%. Given that Cara Therapeutics has higher upside potential than Johnson & Johnson, analysts believe Cara Therapeutics is more attractive than Johnson & Johnson.

Cara Therapeutics has a beta of 0.641, which suggesting that the stock is 35.853% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.522%.

Cara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.33% to investors and pays a quarterly dividend of $1.24 per share. Cara Therapeutics pays -- of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cara Therapeutics quarterly revenues are $2.6M, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Cara Therapeutics's net income of -$12.5M is lower than Johnson & Johnson's net income of $2.7B. Notably, Cara Therapeutics's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 24.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cara Therapeutics is 2.92x versus 4.04x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -488.11% compared to Cara Therapeutics's net margin of -49.65%. Cara Therapeutics's return on equity of -258.41% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Cara Therapeutics has a consensus price target of $1.01, signalling upside risk potential of 117.86%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than Cara Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Cara Therapeutics.

Cara Therapeutics has a beta of 0.641, which suggesting that the stock is 35.853% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Cara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cara Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Cara Therapeutics quarterly revenues are $2.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Cara Therapeutics's net income of -$12.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Cara Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cara Therapeutics is 2.92x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

NeuroMetrix has a net margin of -488.11% compared to Cara Therapeutics's net margin of -256.8%. Cara Therapeutics's return on equity of -258.41% beat NeuroMetrix's return on equity of -41.7%.

Cara Therapeutics has a consensus price target of $1.01, signalling upside risk potential of 117.86%. On the other hand NeuroMetrix has an analysts' consensus of -- which suggests that it could grow by 10104.08%. Given that NeuroMetrix has higher upside potential than Cara Therapeutics, analysts believe NeuroMetrix is more attractive than Cara Therapeutics.

Cara Therapeutics has a beta of 0.641, which suggesting that the stock is 35.853% less volatile than S&P 500. In comparison NeuroMetrix has a beta of 2.182, suggesting its more volatile than the S&P 500 by 118.234%.

Cara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroMetrix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cara Therapeutics pays -- of its earnings as a dividend. NeuroMetrix pays out -- of its earnings as a dividend.

Cara Therapeutics quarterly revenues are $2.6M, which are larger than NeuroMetrix quarterly revenues of $587.3K. Cara Therapeutics's net income of -$12.5M is lower than NeuroMetrix's net income of -$1.5M. Notably, Cara Therapeutics's price-to-earnings ratio is -- while NeuroMetrix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cara Therapeutics is 2.92x versus 1.82x for NeuroMetrix. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -488.11% compared to Cara Therapeutics's net margin of 7.2%. Cara Therapeutics's return on equity of -258.41% beat Sarepta Therapeutics's return on equity of 12.48%.

Cara Therapeutics has a consensus price target of $1.01, signalling upside risk potential of 117.86%. On the other hand Sarepta Therapeutics has an analysts' consensus of $185.10 which suggests that it could grow by 51.85%. Given that Cara Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Cara Therapeutics is more attractive than Sarepta Therapeutics.

Cara Therapeutics has a beta of 0.641, which suggesting that the stock is 35.853% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.767, suggesting its less volatile than the S&P 500 by 23.328%.

Cara Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cara Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Cara Therapeutics quarterly revenues are $2.6M, which are smaller than Sarepta Therapeutics quarterly revenues of $467.2M. Cara Therapeutics's net income of -$12.5M is lower than Sarepta Therapeutics's net income of $33.6M. Notably, Cara Therapeutics's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 79.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cara Therapeutics is 2.92x versus 7.48x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.